Business context and reporting period
The supplied filing is Predictive Oncology Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024—not an Axe Compute Inc. filing. Predictive Oncology applies AI and a 150,000-plus-sample tumor biobank to oncology drug development, provides biologics research services, and sells the FDA-cleared STREAMWAY medical-fluid disposal system. Its three segments are Pittsburgh, Birmingham, and Eagan.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior balance-sheet date |
|---|---|---|
| Revenue | $419,646 | $239,895 |
| Gross profit / margin | $232,231 / approximately 55% | $119,756 / approximately 50% |
| Operating expenses | $4,469,003 | $3,584,739 |
| Net loss | $4,218,843; $1.04 per share | $3,421,802; $0.86 per share |
| Cash used in operating activities | $3,416,021 | $3,427,761 |
| Cash | $5,197,235 | $8,728,660 at December 31, 2023 |
| Total assets / liabilities | $10,601,187 / $6,547,516 | $14,417,249 / $6,145,469 at December 31, 2023 |
| Current assets / current liabilities | $6,561,323 / $4,516,661 | $10,078,431 / $3,951,031 at December 31, 2023 |
Operating cash outflow was largely unchanged year over year. Investing outflow was $3,032 and financing outflow was $112,372, principally repayment of an insurance-premium note. The remaining note payable was $38,036. Lease liabilities totaled $2,567,548, including $2,027,348 long-term. No operating margin was reported as a separate metric; operating loss was $4,236,772.
Material changes versus the prior comparable period
- Revenue increased $179,751, or approximately 75%, primarily due to higher STREAMWAY system sales; Eagan revenue rose to $403,779 from $215,619.
- Gross margin improved to approximately 55% from 50%, also attributed to sales mix.
- Net loss widened by $797,041. General and administrative, operations, and sales and marketing expenses all increased; sales and marketing expense included severance related to a former executive.
- Cash declined by $3,531,425 from year-end 2023. Stockholders’ equity fell to $4,053,671 from $8,271,780.
Outlook, risks, and unusual items
Management does not expect operating revenue to sustain operations in the near term and reports substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. It is evaluating equity or debt financing, other financing arrangements, and potential monetization of businesses or assets. Funding may be unavailable or materially dilutive; without sufficient financing or operating cash, the company may have to curtail operations, default on obligations, or cease operations. The filing provides no specific revenue or earnings guidance.
Customer concentration is notable: one customer represented 50% of Q1 2024 revenue and 43% of accounts receivable at quarter-end. Other disclosed risks include continued cash burn, capital needs, commercialization and partnership uncertainty, competition, intellectual-property and regulatory risks. Management reported effective disclosure controls and no material change in internal control; it reported no material pending legal proceedings and no material changes to the prior annual report’s risk factors.
Important facts for investors to verify
- Confirm the intended issuer: the filing identifies Predictive Oncology Inc. (Nasdaq: POAI), not Axe Compute Inc.
- Assess cash runway, financing availability, and the consequences of the disclosed going-concern uncertainty.
- Review customer concentration and whether STREAMWAY sales growth and improved gross margin can continue.
- Evaluate dilution risk from potential financing; the filing reports 1,799,430 warrants outstanding at March 31, 2024. Common shares outstanding were 4,062,853 at quarter-end and 4,101,776 as of May 10, 2024.